Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Parallel, and Active-controlled Phase III Trial

Trial Profile

Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Parallel, and Active-controlled Phase III Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs Borneol/edaravone (Primary) ; Edaravone
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Sponsors Jiangsu Simcere Pharmaceutical
  • Most Recent Events

    • 12 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 30 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2016.
    • 19 Apr 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top